文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

清热解毒凉血散瘀法治疗脓毒症的Meta分析

[A Meta-analysis of Qingre Jiedu and Liangxue Sanyu method in the treatment of sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2019-01-01
一句话结论纳入20项RCT、1347例脓毒症患者的Meta分析显示,清热解毒凉血散瘀法辅助常规治疗可能降低28天死亡率(RR=0.54,95%CI 0.45-0.65,P<0.00001)。

该Meta分析检索PubMed、Embase、Web of Science、CNKI和万方数据库至2017年12月31日的RCT,纳入20项RCT共1347例脓毒症患者(对照组667例,试验组680例)。对照组采用液体复苏、维持血流动力学稳定、抗感染、改善组织灌注、维持器官功能和营养支持等常规治疗,试验组在常规治疗基础上加用清热解毒凉血散瘀法中药(中成药或中草药)。结果显示试验组28天死亡率显著降低(RR=0.54,95%CI 0.45-0.65,P<0.00001),7天APACHE II评分、PT、APTT、IL-6、TNF-α及7天乳酸均显著下降,但PCT和ICU住院时间无显著差异。作者认为该法可能降低炎症介质释放、改善凝血功能并降低28天死亡率。

要点

  • 纳入20项RCT共1347例脓毒症患者(对照组667例,试验组680例),试验组在常规治疗基础上加用清热解毒凉血散瘀法中药。
  • 28天死亡率:试验组较对照组显著降低(RR=0.54,95%CI 0.45-0.65,P<0.00001)。
  • 7天APACHE II评分试验组较对照组显著降低(MD=-3.86,95%CI -4.82至-2.90,P<0.00001)。
  • 7天PT(MD=-1.72,95%CI -2.29至-1.14,P<0.00001)和APTT(MD=-4.36,95%CI -5.81至-2.91,P<0.00001)试验组较对照组显著缩短。
  • 10天IL-6(MD=-40.33,95%CI -59.55至-21.11,P<0.0001)和TNF-α(MD=-7.26,95%CI -11.31至-3.21,P=0.0004)试验组较对照组显著降低;PCT和ICU住院时间无显著差异。

适用人群与场景

  • 脓毒症患者,来自20项RCT,共1347例(对照组667例,试验组680例)。

处置流程与药物剂量

  • 对照组:脓毒症常规治疗措施,如液体复苏、维持血流动力学稳定、抗感染、改善组织灌注、维持器官功能和营养支持。
  • 试验组:在常规治疗基础上加用清热解毒凉血散瘀法中药治疗,包括中成药或中草药。

研究设计与关键结果

  • 研究类型:Meta分析,纳入20项RCT,共1347例患者(对照组667例,试验组680例);检索PubMed、Embase、Web of Science、CNKI和万方数据库自建库至2017年12月31日。
  • 偏倚风险:综合风险评估显示11项RCT条目风险偏倚未知,9项RCT条目风险偏倚高。
  • 主要终点:28天死亡率试验组较对照组显著降低(RR=0.54,95%CI 0.45-0.65,P<0.00001)。
  • 次要终点:7天APACHE II评分试验组较对照组显著降低(MD=-3.86,95%CI -4.82至-2.90,P<0.00001);7天PT试验组较对照组显著缩短(MD=-1.72,95%CI -2.29至-1.14,P<0.00001);7天APTT试验组较对照组显著缩短(MD=-4.36,95%CI -5.81至-2.91,P<0.00001)。
  • 7天D-二聚体试验组较对照组略有改善但未达统计学显著(MD=-0.13,95%CI -0.37至0.11,P=0.29)。
  • 10天IL-6试验组较对照组显著降低(MD=-40.33,95%CI -59.55至-21.11,P<0.0001);10天TNF-α试验组较对照组显著降低(MD=-7.26,95%CI -11.31至-3.21,P=0.0004)。
  • 7天乳酸试验组较对照组显著下降(MD=-1.30,95%CI -1.91至-0.68,P<0.0001);PCT试验组与对照组无显著差异(MD=-1.57,95%CI -3.25至0.11,P=0.07);ICU住院时间试验组与对照组无显著差异(MD=-4.02,95%CI -8.60至0.56,P=0.09)。
  • 发表偏倚:19项研究报告28天死亡率,漏斗图基本呈漏斗形分布,无潜在发表偏倚(P=0.336)。

证据类型、等级与局限

  • 证据类型:系统评价/Meta分析,纳入20项RCT。
  • 偏倚风险:11项RCT条目风险偏倚未知,9项RCT条目风险偏倚高。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,清热解毒凉血散瘀法可能降低脓毒症患者炎症介质释放、改善凝血功能并降低28天死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To systematically review the effect of Qingre Jiedu and Liangxue Sanyu method in patients with sepsis, and to discuss its effect in the treatment of sepsis.

METHODS: The randomized controlled trials (RCTs) on the treatment of Qingre Jiedu and Liangxue Sanyu method for sepsis published on PubMed, Embase, Web of Science, CNKI and Wanfang database from the construction to December 31st, 2017 were searched by electronical way. Conventional treatment measures for sepsis, such as fluid resuscitation, maintenance of hemodynamic stability, anti-infection, improvement of tissue perfusion, maintenance of organ function and nutritional support were used in the control group. While traditional Chinese medicine treatment based on Qingre Jiedu and Liangxue Sanyu method were applied in the experimental group besides the conventional treatment, including Chinese patent medicine or Chinese herbal medicine. The main outcome was 28-day mortality, and the second outcome was acute physiology and chronic health evaluation II (APACHE II), coagulation function, inflammatory mediators, procalcitonin (PCT), lactic acid (Lac), and the length of intensive care unit (ICU) stay. Two researchers independently searched literatures, collected data and evaluated risk bias. The statistical analysis was completed by RevMan 5.3 and STATA 13.0 software. The funnel plot and Egger test were used to evaluate the potential publication bias of the main outcomes.

RESULTS: A total of 20 RCTs were enrolled in this Meta-analysis, including 1 347 patients, with 667 patients in the control group and 680 patients in the experimental group. Comprehensive risk bias assessment showed that the risk bias of 11 RCT items was unknown, and the risk bias of 9 RCT items was high. Meta-analysis results showed that compared with the control group, the 28-day mortality of the experimental group was significantly lowered [relative risk (RR) = 0.54, 95% confidence interval (95%CI) = 0.45-0.65, P < 0.000 01], the 7-day APACHE II score was significantly lowered [mean difference (MD) = -3.86, 95%CI = -4.82 to -2.90, P < 0.000 01], the 7-day prothrombin time (PT) and activated partial thromboplastin time (APTT) were significantly shortened (PT: MD = -1.72, 95%CI = -2.29 to -1.14, P < 0.000 01; APTT: MD = -4.36, 95%CI = -5.81 to -2.91, P < 0.000 01), the 7-day D-dimer was slightly improved (MD = -0.13, 95%CI = -0.37-0.11, P = 0.29), the 10-day interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were significantly decreased (IL-6: MD = -40.33, 95%CI = -59.55 to -21.11, P < 0.000 1; TNF-α: MD = -7.26, 95%CI = -11.31 to -3.21, P = 0.000 4), the 7-day Lac was significantly declined (MD = -1.30, 95%CI = -1.91 to -0.68, P < 0.000 1), but no significance in PCT (MD = -1.57, 95%CI = -3.25-0.11, P = 0.07) or the length of ICU stay (MD = -4.02, 95%CI = -8.60-0.56, P = 0.09) was found. The results of publication bias assessment showed that 19 studies reported 28-day mortality were basically "funnel-shaped" distribution without potential publication bias (P = 0.336).

CONCLUSIONS: The Meta-analysis showed that Qingre Jiedu and Liangxue Sanyu method may reduce the release of inflammatory mediators, improve the coagulation function, and reduce the 28-day mortality in patients with sepsis.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Cheng L, Jiang H, Chen M, et al. [A Meta-analysis of Qingre Jiedu and Liangxue Sanyu method in the treatment of sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 30707873. doi:10.3760/cma.j.issn.2095-4352.2019.01.015

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。